GHRP-6 vs Hexarelin: What the Research Compares
No head to head randomized trial comparing GHRP-6 with hexarelin appears in the verified literature covered here. Both are synthetic growth hormone secretagogues acting at the ghrelin receptor, and both appear together in one human receptor pharmacology experiment (PMID 17112585). Beyond that overlap, their evidence bases diverge: GHRP-6 literature includes pituitary adrenal testing and CD36 structure activity chemistry, while hexarelin literature includes sleep endocrinology in volunteers and rodent cardiac and analgesia models.
Head to head trials: what the record shows
Among the verified papers covered on this page, no randomized controlled trial directly compared GHRP-6 against hexarelin with assigned comparator arms and a prespecified primary endpoint. That absence is stated plainly here rather than filled in with indirect inference.
A second paper brings both names into one human experiment from a different angle. Researchers tested whether d-Lys-GHRP-6, a modified GHRP-6 analogue used as a ghrelin receptor antagonist in laboratory work, would blunt the endocrine response to acylated ghrelin or to hexarelin in human volunteers, and reported that it did not modify that response (PMID 17112585). The study examined receptor pharmacology using a GHRP-6 derivative as a tool compound, so it is not a comparison of GHRP-6 and hexarelin as secretagogues.
Side by side: separate evidence bases
Because no head to head trial exists in this citation set, the two literatures are set out in parallel below. Nothing in this table ranks the peptides or implies that one is preferable for any purpose.
| Dimension | GHRP-6 | Hexarelin |
|---|---|---|
| Class | Synthetic growth hormone releasing peptide studied as a ghrelin receptor ligand, with analogues also characterized at the CD36 scavenger receptor (PMID 21692501) | Synthetic growth hormone secretagogue described as a ghrelin receptor agonist in rodent work (PMID 32893668) |
| Human endocrine studies in this set | Stimulation of cortisol and ACTH release in patients with Cushing's disease, examined alongside DDAVP (PMID 12809173) | Decreased slow wave sleep with stimulation of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers (PMID 15177700) |
| Other human or ex vivo findings | d-Lys-GHRP-6 did not modify the endocrine response to acylated ghrelin or hexarelin in humans (PMID 17112585) | Stimulated GH release from peripheral lymphocytes (PMID 12397533) |
| Animal models in this set | No rodent efficacy study of GHRP-6 itself appears among the verified papers; the chemistry work used azapeptide analogues at CD36 (PMID 21692501) | Protection of rat cardiomyocytes from in vivo ischemia and reperfusion injury through interleukin-1 signaling (PMID 28321024) and attenuation of antinociceptive tolerance to morphine in rats (PMID 32893668) |
Shared mechanism: the ghrelin receptor
Both peptides belong to the growth hormone secretagogue family, a group whose members act at the growth hormone secretagogue receptor, better known as the ghrelin receptor. Hexarelin has been described explicitly as a ghrelin receptor agonist in rodent pharmacology, where researchers used it to probe receptor involvement in opioid tolerance (PMID 32893668). On the GHRP-6 side, a human study used the derivative d-Lys-GHRP-6 as a receptor antagonist probe and reported that it did not change the endocrine response to acylated ghrelin or hexarelin, a result that illustrates how incompletely the pharmacology of this receptor is mapped in people (PMID 17112585).
Comparative biology has added depth to the receptor picture. Researchers identified, mapped the tissue distribution of and functionally characterized the ghrelin receptor in West African lungfish (PMID 25093625), and a separate group characterized a third ghrelin receptor subtype, GHS-R3a, in channel catfish, reporting novel expression patterns and high affinity for the homologous ligand (PMID 30471349). These papers describe receptor biology across species rather than the behaviour of either peptide in humans.
Where the mechanisms diverge in the literature
GHRP-6 chemistry has been pushed in a direction that hexarelin work in this set has not followed. A structure activity study built azapeptide analogues of GHRP-6 by solid phase submonomer synthesis and characterized them as ligands of the CD36 scavenger receptor (PMID 21692501), indicating a second molecular target of interest for this scaffold beyond the ghrelin receptor. Hexarelin literature in this set leans toward tissue level outcomes, including a rat model in which the peptide protected cardiomyocytes from ischemia and reperfusion injury through interleukin-1 signaling (PMID 28321024). A review of growth hormone releasing peptides and the cardiovascular system placed this class of compounds within cardiovascular physiology more broadly (PMID 10790589).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat each literature actually measured
GHRP-6
The human GHRP-6 work in this set is diagnostic in character. In patients with Cushing's disease, the study reported that GHRP-6 was able to stimulate cortisol and ACTH release, and the investigators compared that response with DDAVP (PMID 12809173). The endpoint there was hormone response in a defined patient population, not a performance, physique or longevity outcome. For a broader orientation to this peptide, see the GHRP-6 overview.
Hexarelin
The hexarelin literature spans human sleep endocrinology, cell level secretion and rodent disease models. In healthy volunteers, the study reported that hexarelin decreased slow wave sleep and stimulated the secretion of GH, ACTH, cortisol and prolactin during sleep (PMID 15177700). In an ex vivo setting, researchers reported that hexarelin stimulated GH release from peripheral lymphocytes, extending the idea of growth hormone production outside the pituitary (PMID 12397533). In rats, hexarelin attenuated antinociceptive tolerance to morphine (PMID 32893668) and protected cardiomyocytes after ischemia and reperfusion (PMID 28321024).
Regulatory status
Neither peptide appears in the verified literature as an approved human medicine with a marketing authorization. Material offered for laboratory work is commonly labelled for research use only, a labelling category that is distinct from approval for human treatment.
Tracking research? Log entries with dates, lots and notes: records, never plans.
Get the appReported effects and adverse events: What Studies Report
Safety information in this citation set is limited and comes mostly from small physiological studies rather than from trials designed to count adverse events.
- Non selective hormone output. In healthy volunteers, the study reported that hexarelin stimulated ACTH, cortisol and prolactin in addition to GH during sleep, so the hormonal effect was not confined to the growth hormone axis (PMID 15177700).
- Sleep architecture. The same volunteer study reported a decrease in slow wave sleep after hexarelin (PMID 15177700).
- Adrenal axis activation with GHRP-6. In patients with Cushing's disease, researchers reported that GHRP-6 stimulated cortisol and ACTH release (PMID 12809173), a property that was the point of the diagnostic test rather than an incidental finding.
- Antagonist pharmacology is unsettled. A human study reported that d-Lys-GHRP-6 did not modify the endocrine response to acylated ghrelin or hexarelin, which complicates assumptions about blocking these effects (PMID 17112585).
- Animal findings are not human safety data. Cardiac and analgesia tolerance results in rats were mechanistic outcomes in disease models (PMID 28321024, PMID 32893668) and were not designed to establish tolerability in people.
What this comparison cannot answer
Without a trial that randomized participants to GHRP-6 or hexarelin and measured the same endpoint in both arms, the published record covered here cannot support statements about relative potency, relative duration, relative safety or relative suitability for any goal. The two peptides appear together in one shared pharmacology experiment that used a GHRP-6 derivative as an antagonist probe against hexarelin and ghrelin (PMID 17112585). Everything else sits in separate literatures with different species, different endpoints and different eras of investigation.
This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, symptom or treatment decision. It summarises what published studies reported and does not describe how any substance should be used.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeReferences
- The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway (International Heart Journal, 2017)
- Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin (Drug Testing and Analysis, 2015)
- Identification, tissue distribution and functional characterization of the ghrelin receptor in West African lungfish, Protopterus annectens (General and Comparative Endocrinology, 2014)
- Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats (Canadian Journal of Physiology and Pharmacology, 2021)
- d-Lys-GHRP-6 does not modify the endocrine response to acylated ghrelin or hexarelin in humans (Neuropeptides, 2007)
- GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP (Journal of Endocrinological Investigation, 2003)
- Growth hormone secretagogue (GHS) analogue, hexarelin stimulates GH from peripheral lymphocytes (Experimental and Clinical Endocrinology & Diabetes, 2002)
- Structure-activity relationships of GHRP-6 azapeptide ligands of the CD36 scavenger receptor by solid-phase submonomer azapeptide synthesis (Journal of the American Chemical Society, 2011)
- Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers (Psychoneuroendocrinology, 2004)
- Growth hormone-releasing peptides and the cardiovascular system (Annales d'Endocrinologie, 2000)
- Characterization of a third ghrelin receptor, GHS-R3a, in channel catfish reveals novel expression patterns and a high affinity for homologous ligand (Comparative Biochemistry and Physiology Part A, 2019)
- In vitro models for metabolic studies of small peptide hormones in sport drug testing (Journal of Peptide Science, 2015)
Frequently asked questions
Has any trial compared GHRP-6 and hexarelin head to head?▾
No randomized head to head trial appears in the literature covered here. The one human experiment that included both used a GHRP-6 derivative as a receptor antagonist probe and did not compare the two as secretagogues (PMID 17112585).
Do GHRP-6 and hexarelin act on the same receptor?▾
Both belong to the growth hormone secretagogue class associated with the ghrelin receptor. Hexarelin was described as a ghrelin receptor agonist in rat work on morphine tolerance (PMID 32893668). A human study used the GHRP-6 derivative d-Lys-GHRP-6 as an antagonist probe and reported it did not modify responses to acylated ghrelin or hexarelin (PMID 17112585).
What did human studies report about hexarelin and sleep?▾
In healthy volunteers, the study reported that hexarelin decreased slow wave sleep while stimulating secretion of growth hormone, ACTH, cortisol and prolactin during sleep (PMID 15177700). That pattern shows the hormonal response was not limited to growth hormone. The report described physiological observations in a research setting and did not establish any use.
What was GHRP-6 studied for in patients?▾
Researchers examined GHRP-6 in patients with Cushing's disease and reported that it stimulated cortisol and ACTH release, with the response compared against DDAVP (PMID 12809173). The context was endocrine testing of the pituitary adrenal axis. Separate chemistry work characterized GHRP-6 azapeptide analogues as ligands of the CD36 scavenger receptor (PMID 21692501).
Are there animal studies specific to hexarelin?▾
Yes. One rat study reported that hexarelin protected cardiomyocytes from in vivo ischemia and reperfusion injury through interleukin-1 signaling (PMID 28321024). Another reported that hexarelin attenuated antinociceptive tolerance to morphine in rats (PMID 32893668). Both were mechanistic animal models, and a review placed growth hormone releasing peptides within cardiovascular physiology more broadly (PMID 10790589).
What does comparative receptor research add to this topic?▾
It maps the biology of the target rather than the peptides themselves. Researchers identified, mapped and functionally characterized the ghrelin receptor in West African lungfish (PMID 25093625), and another group characterized a third ghrelin receptor, GHS-R3a, in channel catfish with novel expression patterns and high affinity for the homologous ligand (PMID 30471349).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.